emricasan
Small moleculeexperimental
Emricasan is a potential drug invented in 1998 by Idun Pharmaceuticals. The drug was acquired by Pfizer in 2005 and then sold to Conatus Pharmaceuticals in 2010. Conatus in turn licensed emricasan to Novartis in 2017 for exclusive development and commercialization. — Wikipedia
Clinical trial activity
17 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
12
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2003 (NCT00080236)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 2
- Cholestasis · Phase 2
- COVID-19 · Phase 1
- Diabetes Mellitus · Phase 1/Phase 2
- Digestive System Diseases · Phase 1
- Fibrosis · Phase 2
- Hepatitis · Phase 2
- Hepatitis, Alcoholic · Phase 2
- Hepatitis C, Chronic · Phase 2
- Hypertension, Portal · Phase 2
- Kidney Diseases · Phase 1
- Kidney Failure, Chronic · Phase 1
- Liver Cirrhosis · Phase 2
- Liver Diseases · Phase 2
- Liver Failure · Phase 2
- Liver Failure, Acute · Phase 2
- Liver Transplantation · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 2
- Renal Insufficiency · Phase 1
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F- Mol. weight
- 569.51 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEmricasan ↗
- ChEMBLCHEMBL197672 ↗
Also known as
- 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
- emricasan
- emricasan
- emricasan
- emricasan
- emricasan
- idn6556
- idn 6556
- idn-6556
- idn-6556
- idn-6556
- idn-6556
- pf03491390
- pf 03491390
- pf-03491390
- pf-03491390
- pf-03491390
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04803227 | Phase 1 | Mar 11, 2021 | Histogen, State University of New York, Brooklyn |
| NCT03462576 | N/A | Jun 28, 2017 | Conatus Pharmaceuticals, Meridien Research |
| NCT03205345 | Phase 2 | Jun 28, 2017 | Conatus Pharmaceuticals |
| NCT02960204 | Phase 2 | Oct 17, 2016 | Conatus Pharmaceuticals |
| NCT03439189 | N/A | Aug 28, 2016 | Conatus Pharmaceuticals, Meridien Research |
| NCT02686762 | Phase 2 | Jan 1, 2016 | Conatus Pharmaceuticals |
| NCT02230683 | Phase 2 | Aug 1, 2014 | Conatus Pharmaceuticals |
| NCT02230670 | Phase 2 | Aug 1, 2014 | Conatus Pharmaceuticals |
| NCT02138253 | Phase 2 | May 1, 2014 | Conatus Pharmaceuticals |
| NCT02121860 | Phase 1 | Apr 1, 2014 | Conatus Pharmaceuticals |
| NCT02077374 | Phase 2 | Mar 1, 2014 | Conatus Pharmaceuticals |
| NCT02039817 | Phase 1 | Jan 1, 2014 | Conatus Pharmaceuticals |
| NCT01937130 | Phase 2 | Sep 1, 2013 | Conatus Pharmaceuticals, University of Nottingham |
| NCT01912404 | Phase 2 | Jul 1, 2013 | Conatus Pharmaceuticals, National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT01653899 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2012 | Conatus Pharmaceuticals, University of Alberta |
| NCT00088140 | Phase 2 | Jul 1, 2004 | Conatus Pharmaceuticals, Idun Pharmaceuticals |
| NCT00080236 | Phase 2 | Nov 1, 2003 | Conatus Pharmaceuticals, Idun Pharmaceuticals |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Conatus Pharmaceuticals | For profit | 16 | 13 | 3 | 2003 |
| Idun Pharmaceuticals | For profit | 2 | 0 | 1 | 2003 |
| Meridien Research | For profit | 2 | 2 | 1 | 2016 |
| Histogen | For profit | 1 | 1 | 1 | 2021 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 0 | 1 | 2013 |
| State University of New York, Brooklyn | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Alberta | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Nottingham | Academic/Hospital | 1 | 0 | 1 | 2013 |
8 organizations
Page 1 / 1